替吉奥联合奥沙利铂治疗晚期胃癌的研究

Research of S1 combined with oxaliplatin in the treatment of advanced gastric cancer

目的:观察替吉奥联合奥沙利铂治疗晚期胃癌的临床疗效。方法:46例晚期胃癌患者随机分为治疗组和对照组,治疗组22例采用替吉奥胶囊40mg/(m2.d),分2次口服,第1-14天;奥沙利铂135(mg/m2.d),静脉滴注,第1天,对照组24例采用5-FU 600mg/(m2.d)微量泵进行8h持续静脉滴注,第1-5天;奥沙利铂135mg/(m2.d),静脉滴注,第1天,两组均以28d为1个周期,2周期后评价疗效。结果:治疗组和对照组有效率差异无统计学意义P>0.05,在KPS评分,骨髓抑制和胃肠道反应方面两组差异有统计学意义P<0.05。结论:替吉奥联合奥沙利铂治疗晚期胃癌与5氟尿嘧啶(5-FU)联合奥沙利铂相比,近期疗效相似,但不良反应明显减轻,值得进一步研究及推广。

Objective：To investigate the effect of Tegafur（S-1） combined with Oxaliplatin for the advanced gastric cancer.Methods：All 46 advanced gastric cancer patients were randomly divided into two groups,the treatment group 22 patients treated with Tegafur（S-1） combined with oxaliplatin,the control group,24 patients were treated with 5-fluorouracil（5-FU） combined with oxaliplatin.Results：There was no significant difference in the effective rate between the control group and experimental group（P 0.05）,the KPS score,bone marrow suppression and gastrointestinal tract had statistically significance between the two groups（P 0.05）.Conclusion：The short term effects of Tegafur combined with Oxaliplatin for the treatment of advanced gastric cancer and 5-fluorouracil and oxaliplatin are similar,but the side effects of Tegafur combined with Oxaliplatin are significantly reduced,it is worthy to furtherly research and promotion.